Drug intelligence / Profile preview

Y6

Development stage: Preclinical
Modality: Small Molecules

Overview

Y6 is a synthesized derivative of epigallocatechin-3-gallate (EGCG), a main constituent of green tea. It was developed to overcome the limitations of EGCG, such as its susceptibility to oxidation, low lipid solubility, and poor bioavailability. Y6 has demonstrated the ability to reduce the cardiotoxicity and enhance the antitumor efficacy of daunorubicin, particularly against human hepatocellular carcinoma, by inhibiting the expression of carbonyl reductase 1.

Other names: 5,3′,4′,3″,4″,5″-6-O-ethyl-EGCG

Beyond the preview

Go deeper on Y6.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Y6.

Explore the full profile